The phagocytic cells of the peripheral blood mononuclear population are a major source of serine proteases that play essential roles in the pathophysiology of tissue homeostasis, inflammation, and blood coagulation (1, 2). The neutral proteases secreted by stimulated monocytes and/or macrophages include: elastase (3), plasminogen activators (4–7), collagenase (8, 9), as well as components of both the coagulation (10) and complement pathways (11). In addition to contributing to the structural reorganization of tissue, particularly at inflammatory sites, some of these proteases also appear to be instrumental in the control of mononuclear cell and tumor cell migration (12–14), as well as both the cytolytic (15) and mitogenic activities of macrophages (16).

The mechanism universally used to regulate the destructive effects of serine proteases is the coordinated synthesis of specific endogenous inhibitors (1, 2, 17). These serine protease inhibitors constitute a family of closely related proteins (the Serpin superfamily [18]), with the common functional feature that they trap the protease by presenting a reactive site that provides an ideal pseudosubstrate (17). The target specificity of each Serpin (i.e., Met or Val for elastase; Leu for chymase; Arg for thrombin) is determined by the amino acid residue located at its reactive center. Normally this residue is the same amino acid found on the NH₂-terminal side of the peptide bond to be cleaved by the protease in the legitimate substrate (17). This crucial amino acid forms the basis for a Serpin classification scheme (e.g., Met-Serpin, Arg-Serpin etc.) (18). The enzyme and its inhibitor bind tenaciously to form a complex that is typically stable to boiling in detergent (19), but is susceptible to neutrophilic cleavage with ammonium hydroxide (20). Failure or lack of regulation of these potent proteolytic enzymes is known to lead to severe pathological effects (18, 21). For example, a genetic
or environmentally induced deficiency in the most prevalent serum Met-Serin, $\alpha_1$ protease-inhibitor (API),\(^1\) has been demonstrated to account for the loss of pulmonary function associated with emphysema (22). Conversely, an overproduction of the Arg-Serin that inhibits the action of the plasminogen activator (PA) found in plasma, has been correlated with human thromboembolic disease (23).

Here we report the cDNA cloning, sequence, and chromosomal assignment of an Arg-Serin gene transcribed by LPS-stimulated human monocytes that is tentatively identified as the monocyte/macrophage-derived plasminogen activator-inhibitor (PAI-2; nomenclature suggested by the International Committee Thrombosis Haemostasis, Subcommittee on Fibrinolysis, June 8, 1986) activity reported by several laboratories (5-7, 24, 25). Our isolation of a monocyte-derived cDNA coding for a PAI different from the endothelial cell PAI (now designated PAI-1) clone recently reported (26-28) substantiates the previous conclusion, based upon biochemical and immunological criteria, that these two molecules are distinct from one another (5, 29, 30). However, our finding that mRNA for the monocyctic PAI-2 is synthesized in substantial quantities by LPS-stimulated endothelial cells brings into question the assumption that PAI-1 secreted by endothelial cells is the primary PAI responsible for regulation of vascular fibrinolysis (31). As a naturally occurring regulator of urokinase-type plasminogen activator activity (u-PA), this monocyte-derived Arg-Serin may have utility both as a substitute for e-aminocaproic acid (EACA) in the therapeutic modulation of fibrinolysis (32), as well as in the inhibition of tumor cell infiltration, metastasis, and growth (13, 14, 33).

Materials and Methods

Molecular Cloning of Human Monocyte cDNA Library. The preparation of the cDNA library from poly(A)$^+$ RNA isolated from LPS-stimulated, human peripheral blood monocytes is described in detail elsewhere (34, 35). The clone pcD-1214 (Fig. 1) carried in the Okayama-Berg expression vector (36) was characterized as harboring an ~2 kbp pair (kbp) cDNA insert coding for a stimulation-specific mRNA, by virtue of its hybridization exclusively to cDNA probes made from stimulated monocyte poly(A)$^+$ RNA (data not shown). This clone was used as a negative control during characterization of the cDNA for IL-1$\beta$ from this same library (34).

DNA Sequencing and Analysis. Fragments of the pcD-1214 cDNA were subcloned into M13 vectors in preparation for DNA sequencing by the dideoxynucleotide chain termination method (37). Two different sequencing strategies were undertaken, both using $\alpha$[35S]dATP (DuPont NEN Research Products, Boston, MA) as the isotopic tracer and a universal primer. The first approach used a 2.3-kbp Xho I fragment (Fig. 1), which was either subcloned intact into Sal I-digested M13mp9, or digested with a variety of restriction endonucleases to generate convenient subfragments for both sequencing and subcloning into appropriately digested M13mp8 or M13mp9 vectors. These subclones were carried in the Escherichia coli host JM103 (38).

The second approach used the deletion subcloning method of Dale et al. (39). Two M13mp9 subclones containing the entire pcD-1214 Xho I fragment cloned in opposite

---

\(^1\) Abbreviations used in this paper: API, $\alpha_1$-protease inhibitor; ATIII, antithrombin III; EACA, e-aminocaproic acid; ETAF, epidermal thymocyte-activating factor; GTC, guanidinium isothiocyanate; MAS, monocyte Arg-Serin; MDP, muramyl dipeptide; ORF, open reading frame; PA, plasminogen activator; PAI, plasminogen activator-inhibitor; TNF, tumor necrosis factor; t-PA, tissue-type plasminogen activator; TSST-1, toxic shock syndrome toxin; u-PA, urokinase-type plasminogen activator.
Restriction map (not to scale) of cDNA clone pcD-1214 isolated from an LPS-stimulated, human monocyte library constructed in the Okayama and Berg (36) expression vector. Only sites for restriction enzymes that cleave once or twice within the cDNA insert (solid area) are indicated. Portions of the shuttle vector derived from SV40 (shaded) are distinguished from the pBR322 segments (line and open area).

Nucleotide sequence obtained from the M13 subclones generated as described above was assembled using computer programs (40). Subsequent computer analysis of the completed sequence was performed using a variety of software from both the University of Wisconsin (Madison, WI) Genetics Computer Group (UWGCG) (41) and National Biomedical Research Foundation (NBFR; Washington, DC) packages (42, 43).

Northern Blot Analysis. Poly(A)+ RNA isolated from guanidinium isothiocyanate (GTC)-extracted human monocytes as described previously (34) was fractionated on 1.5% formaldehyde-agarose gels (44), electroblotted to Genescreen membranes (DuPont New Research Products), and hybridized in the presence of 50% formamide/10% dextran sulphate with a 1,256-bp Pst I-Dra I pcD-1214 fragment (Figs. 1 and 3B) according to the protocol developed for use with Genescreen by the manufacturer. The cDNA probe was isolated and nick-translated using established procedures. Samples (1 μg) of the Bethesda Research Laboratories (Bethesda, MD)–Gibco Laboratories (Grand Island, NY) RNA ladder were run in adjacent lanes on the same gel for use as molecular weight markers. These standards were visualized after blotting by staining the Genescreen strips with ferri-dye (45).

Chromosomal Assignment. The gene complementary to the pcD-1214 cDNA sequence
was assigned to a particular human chromosome by Southern blot analysis of mouse- 
human somatic cell hybrid genomic DNA as described previously (46). A panel of hybrid 
cell lines was obtained, selected, and evaluated for their human chromosomal content as 
published (47–49). Human, mouse, and hybrid genomic DNAs were digested with Bgl II, 
fractionated by electrophoresis in 0.7% agarose gels and blotted to Genescreen (DuPont 
NEN Research Products) membranes. These blots were also probed with the internal 
1,256-bp Pst I–Dra I fragment isolated from the pcD-1214 plasmid and nick translated 
in the presence of α-[32P]dCTP (DuPont NEN Research Products) to >10^8 cpm/μg by 
conventional techniques. The conditions for membrane hybridization, washing, and 
autoradiography were all as described previously (46).

In Vitro Translation. The pcD-1214 cDNA insert was subcloned as a 3′ truncated 
(pcD-1214ΔDx) 1.63-kbp Pst I–Dra I fragment (Figs. 1 and 3B) into the expression vector 
pSP64 (Promega Biotech, Madison, WI) polylinker region in preparation for in vitro 
transcription using Eco RI linearized template plasmid DNA and SP6 RNA polymerase 
(Promega Biotech) as described by the manufacturer. Uncapped RNA transcripts were 
translated in a rabbit reticulocyte lysate in the presence of [35S]methionine (DuPont NEN 
Research Products) and analyzed by SDS-PAGE as previously described (34).

Results

Characterization of the Stimulation-specific Clone pcD-1214. Restriction enzyme 
analysis of pcD-1214 plasmid revealed a cDNA insert of ~2 kb in length (data 
not shown). Characterization of the mRNA complementary to the pcD-1214 
insert by Northern blot hybridization to monocyte poly(A)+ RNA revealed a 
single species of mRNA ~2,000 nucleotides (nt) in length, the expression of 
which is clearly initiated by stimulation (either adherence or LPS) of human 
monocytes (Fig. 2, lanes 1–4). From this initial analysis, it appeared that the pcD- 
1214 insert was probably a full-length copy of the template mRNA. A minor, 
higher molecular size RNA (~6 kb) that hybridizes to the pcD-1214 probe was 
seen in samples containing relatively more 2-kb mRNA (e.g., Fig. 2, lane 4). 
Since the poly(A)+ RNA preparations used in this study were prepared from 
GTC cell lysates, this high-molecular-weight species may represent a stable 
splicing intermediate.

A preliminary survey of pcD-1214 gene expression in IL-1-producing cells by 
Northern blot analysis revealed that transcription of this gene is linked to cellular 
stimulation. For example, endothelial cells from human umbilical vein synthesize 
appreciable amounts of pcD-1214 mRNA only when stimulated with LPS (Fig. 2, 
lanes 7 and 8). Similarly, cells of the histiocytic lymphoma cell line U937 activate 
the pcD-1214 gene on exposure to toxic shock syndrome toxin (TSST-1) (50) 
(Fig. 2, lane 5), whereas the keratinocyte line Colo 16 (Fig. 2, lane 6), which is a 
constitutive producer of IL-1 (epidermal thymocyte-activating factor [ETAF]) 
(51), does not transcribe the pcD-1214 gene.

The precise kinetics of expression of the pcD-1214 gene in monocytic cells are 
presently under investigation, but preliminary data from nuclear run-off exper- 
iments in the monocytic leukemia line THP-1 (data not shown) indicate that, in 
common with the IL-1β gene, the pcD-1214 gene may undergo transient expression 
of the type found in association with many oncogenes and competence factors (52). This conclusion is consistent with the Northern blot data presented 
in Fig. 2, which indicate that the levels of pcD-1214 mRNA in peripheral blood 
monocytes 4 h after LPS stimulation (lane 4) are considerably higher than those 
seen at 12 h after stimulation (lane 1).
Nucleotide Sequence of Monocyte cDNA pcD-1214. Dideoxynucleotide sequencing of the pcD-1214 overlapping subclones generated a complete 1,900-bp sequence from both strands of the cDNA. The nucleotide sequence of the coding strand, together with its deduced amino acid sequence, are shown in Fig. 3A, and a compilation of significant structural features of both amino acid and nucleotide sequences are summarized on the restriction map shown in Fig. 3B.

Open Reading Frames. Analysis of the compiled nucleotide sequence revealed the longest open reading frame (ORF) to be 1,248 nt commencing with the ATG at position 73 and terminating at nucleotide 1,320 (TAA) of frame 1 as represented in Fig. 3A. The amino acid sequence coded for by this ORF conforms well to coding criteria such as codon utilization, amino acid constituency, and positional base preference as determined by analysis with several different algorithms (41, 53, 54). The initiator methionine bears a number of the features that seem to characterize the majority of eukaryotic mRNAs sequenced thus far. For example, it is the closest to the 5' end of the sequence, conforms perfectly at crucial positions (capitalized below) to the Kozak consensus (ccRccATGG), and is preceded by both in-frame (TAA at -27) and out-frame (TGA at -7) terminators (55).

5' and 3' Untranslated Regions. Although we have no direct evidence (e.g., from primer extension) to indicate that the 5' noncoding sequence represented by the 72 bp of the cDNA shown in Fig. 3A is complete, both the size of the complementary mRNA on Northern blots (see Fig. 2) and the fact that the cDNA sequence in pcD-1214 begins with a purine argue in favor of a full-length clone. The 3' non-translated sequence of 580 bp contains four AATAAA (underlined in Fig. 3A) consensus polyadenylation signals (56), in addition to the overlapping pair 17–26 bp proximal to the poly(A) tail in this clone. It appears that certain of these upstream polyadenylation signals in the pcD-1214 gene transcripts may be used by some cells as sites for alternate processing of mRNA. Northern blots of THP-1 cell RNA indicate that the processed mRNA for this gene in these monocytic-like cells is ~500 nt shorter than the 2-kb species found in monocytes and U937 cells (data not shown). Interestingly, there is a poly(A) addition signal located at position 1,456–1,461 in the pcD-1214 nucleotide
FIGURE 3. (A) Nucleotide sequence of plasmid pcD-1214 cDNA 1,900-bp insert (nucleotides numbered above the lines). The 415-amino-acid polypeptide encoded by this sequence is indicated by three-letter code (amino acids numbered down left margin). Cysteine residues are capitalized (CYS) and potential N-linked glycosylation sites are shown by an asterisk. The solid arrowhead between Ala22 and Ser23 represents the proposed cleavage site for the signal peptide, and the putative reactive center (P, residue) Arg33 for this Serpin is indicated with a broad, open arrow. The 30 carboxyl amino acids (residues 347-376) that match the recently published (30) sequence of the tryptic peptide from PAI-2 are boxed. Nucleotide sequences of interest are highlighted as follows: 5' translational terminators, overlined; polyadenylation signals, underlined; 3' AT-rich repeats, boxed. These sequence data have been submitted to the EMBL/GenBank Data Libraries under the accession number Y00630.

(B) Restriction map of pcD-1214 cDNA indicating relative positions of rare restriction enzyme sites, the ORF (shaded box), cysteine residues (C), asparagine-linked glycosylation sites (N), putative Serpin P, reactive center (P), polyadenylation signal sequences (W) and conserved 3' untranslated AT-rich sequence (TTATTTAT).
Another feature of particular interest within the 3' untranslated region of this clone (positions 1,597–1,604) is an 8-nt sequence (TTATTTAT) recently reported (57) to be conserved in genes encoding inflammatory mediators, some oncogenes, and growth factors. In fact, the degree of homology to tumor necrosis factor α (TNF-α) mRNA extends to a perfect match over a stretch of 13 nt and there are four flanking, partial repeats (>6 nt homology) of the 8-mer consensus sequence within the 3'-untranslated region of the pcD-1214 cDNA (Fig. 3A). The precise significance of this conserved 3' sequence is not yet clear, although recent work by Shaw and Kamen (58) suggests that it may be related to mRNA lability and possibly provide a target for a specific RNase involved in rapid message turnover.

Properties of the Predicted Protein. The nucleotide sequence shown in Fig. 3A can code for a 415-amino-acid long polypeptide of 46,596 molecular weight. This polypeptide has a hydrophobic NH₂-terminus (14 of the first 20 amino acids are nonpolar), and therefore probably represents the precursor to a secreted protein. A comparison of the NH₂-terminal sequence of the predicted protein with both the consensus sequences for known signal peptides (59) and a putative signal peptidase recognition site (60), suggests that removal of the leader sequence would occur between the Ala₂₂ and Ser₂₅ residues of the pcD-1214 polypeptide (filled arrowhead in Fig. 3A). This posttranslational processing of the precursor polypeptide would yield an extracellular protein with a molecular weight around 43,000 containing three potential sites for N-linked glycosylation (Asn-X-Ser/Thr, where X is not Pro [61]) and four of the five cysteine residues found within the 415-amino-acid long precursor polypeptide (see Fig. 3, A and B). The net charge of both the predicted precursor and mature polypeptides is -9. Therefore, in the absence of glycosylation, this protein would have an acidic isoelectric point.

Homology of the Predicted Protein. A search of the NBRF protein sequence database using the Lipman and Pearson (62) algorithm FASTP revealed that the polypeptide encoded by the pcD-1214 clone contained substantial homology to members of the serine protease inhibitor (Serpin) superfamily (63). The degree of amino acid homology between the amino acid sequence predicted from the pcD-1214 clone and the Serpins indicated by this preliminary analysis (data not shown) was sufficiently strong (e.g., antithrombin III (ATIII), 33%; OVA 39%; API, 31%) to suggest a tentative identification of the pcD-1214 polypeptide as a monocyte-derived Serpin. A more stringent assessment of the degree of relatedness between this monocyte Serpin and other human protease inhibitors was obtained by use of the NBRF program ALIGN. Fig. 4 shows the optimized alignments of the carboxyl segments of three human Serpins against the monocyte Serpin. Unlike FASTP, ALIGN takes into account all potential conservative replacements in aligning sequences. Boxed regions in Fig. 4 contain structurally similar amino acids grouped according to the classification of Toh et al. (64). The degree of sequence relatedness is scored as the number of standard deviation (SD) units the alignment is displaced from an alignment of two sequences after amino acid randomization. The align scores of 16–23 SD obtained (see table in
Figure 4. Computer alignment of the COOH-terminal segments of selected Serpin polypeptides (subscript, number of amino acids in each protein). Perfectly matched amino acids are indicated by a vertical line and regions of structurally similar amino acids are boxed. The reactive center P₁ residue that is crucial for substrate specificity and classifies each Serpin is indicated by an arrow. The degree of relatedness of these Serpins is indicated by tabulation of data (both Align Scores and percent amino acid homology) obtained by use of the ALIGN algorithm (see Results for explanation).

Fig. 4) in this analysis indicate that the probability that the monocyte Serpin is not related to ATIII, API, or endothelial cell plasminogen activator–inhibitor (PAI-1) is much less than 1 in 10²⁵ (42). As indicated in Fig. 4 (open arrow), the
high degree of perfect homology around the known reactive center residues in several of these Serpins allowed for classification of the monocyte antiprotease as an Arg-Serpin (MAS) (18).

**Chromosomal Assignment of the Monocyte Arg-Serpin Gene.** Genomic DNA extracted from a series of human-mouse somatic cell hybrids and digested with Bgl II was analyzed by Southern blotting for the segregation of the monocyte Arg-Serpin gene with human chromosomes. The blots were probed with the 1,256-bp Pst I–Dra I fragment from pcD-1214. Fig. 5 shows that this probe hybridized strongly to 4.7- and 6.8-kbp Bgl II fragments of human DNA (lane 7) and crosshybridized weakly to a 15-kbp mouse fragment (lane 6). Hybrid DNAs that contained both mouse and human sequences complementary to the Arg-Serpin probe (Fig. 5, lanes 1–3, 5) were readily distinguishable in this analysis from genomic DNA that contained only the mouse gene (lane 4). Fig. 6 presents the data obtained from Southern blot analysis of 32 independent hybrid lines with respect to the segregation of the Arg-Serpin probe and specific human chromosomes. These results allowed the unambiguous assignment of the monocyte Arg-Serpin gene to human chromosome 18, since in every instance, the presence or absence of the human fragment pattern correlated with the retention and loss, respectively, of this chromosome.

**In Vitro Synthesis of Monocyte Arg-Serpin Polypeptide.** To confirm the fidelity of the deduced ORF postulated for the monocyte Arg-Serpin encoded within the pcD-1214 cDNA, a subclone containing the SP6 promoter was used to generate in vitro transcripts which were subsequently translated in reticulocyte lysates containing [35S]methionine. This resulted in the synthesis of a predominant, radiolabeled polypeptide with an $M_r$ of approximately 42,000 when analyzed by SDS-PAGE (Fig. 7). The size of this protein corresponds well to that predicted from the nucleotide sequence (46,000 mol wt) and is within the accepted limits of variability for SDS-PAGE analysis. The minor species of labeled polypeptides with a smaller $M_r$ seen in this analysis (Fig. 7) probably represent translation products derived from initiation at internal AUG codons with a strong Kozak consensus sequence (−3 purine and G at +4) (55). There are six such positions (around residues 39, 41, 196, 327, 329, 359) within the pcD-1214
**FIGURE 6.** Segregation of Arg-Serpin probe (pcD-1214) with human chromosomes in human-mouse cell hybrids. The pcD-1214 probe was hybridized to Southern blots containing Bgl II-digested DNA from the human-mouse cell hybrids listed in the Figure. (t) Indicates a translocated piece (see translocations for details) of the chromosome is present, but not an intact chromosome. The translocations (t) were not used in calculating the percent discordancy. The Arg-Serpin segregation was determined by scoring the presence (+) or absence (−) of human bands in the hybrids on the blots. The data are compiled from 32 somatic cell hybrids between 13 unrelated human, and 4 mouse cell lines. The hybrids were characterized by chromosome analysis, mapped enzyme markers, and partly by mapped DNA probes. Concordant hybrids either retained or lost the Arg-Serpin gene, together with a specific human chromosome. Discordant hybrids either retained the gene, but not a specific chromosome, or the reverse. Percent discordancy indicates the degree of discordant segregation for a marker and a chromosome. A 0% discordancy is the basis for chromosome assignment.

transcripts. Internal initiation of this type has been described elsewhere for eukaryotic translation systems (65, 66).

**Discussion**

Nucleotide sequencing of the stimulation-specific clone pcD-1214 isolated from an LPS-stimulated, human monocyte cDNA library (34, 35) revealed an ORF
coding for the precursor to a secreted polypeptide of 415 amino acids with a calculated molecular weight of 46,596 and a 22 residue signal peptide sequence. The legitimacy of this reading frame was established by reticulocyte lysate translation of SP6-generated cDNA transcripts to yield a polypeptide with an apparent \( M_r \) of 42,000 in SDS-polyacrylamide gels (Fig. 7). Alignment of the predicted amino acid sequence with the sequences of other proteins recorded in the NBRF database or others recently published (27, 28) identified this human monocyte product as being a member of the Serpin (antiprotease) superfamily (63). The highest degree of homology between the Serpins is generally found within the hydrophobic regions located at the COOH-termini, particularly around the reaction center that determines target specificity (21). Taking advantage of this homology to optimize alignment, the monocyte Serpin was found to possess an arginine (Arg\(_{880}\)) residue within the reactive center at the crucial \( P_1 \) position. This feature places this monocyte antiprotease within the Arg-Serpin subgroup, which includes ATIII and the PAI-1. In common with all Serpins sequenced to-date, the hinge residue at \( P_{17} \) is glutamic acid (18). Both overall amino acid homology and alignment scores (see Fig. 4) suggest that the monocyte Arg-Serpin is marginally more closely related to ATIII than to PAI-1.

A recently published (30) partial amino acid sequence (30 carboxyl residues) of monocyte-derived PAI-2 was found to exactly match residues 347–376 (boxed in Fig. 3A) of the amino acid sequence deduced from our clone pCD-1214. Perfect homology over 30 amino acid residues strongly suggests that the monocyte Arg-Serpin identified in this is the same protein isolated and characterized biochemically from U937 cells by Kruithof et al. (30) and now classified as PAI-2. Northern blots of mRNA from stimulated U937 cells probed with the
monocyte Arg-Serpin clone confirm transcriptional activity of this gene in these cells (Fig. 2, lane 5). Definitive confirmation that our monocyte cDNA clone pcD-1214 codes for PAI-2 will await functional assays of the recombinant protein (e.g., PA substrate binding assay by SDS-PAGE analysis of substrate-inhibitor complex; kinetic analysis of PA substrate inhibition). However, a brief report appeared recently (67) on the isolation of PAI-2 clones from a human placental cDNA library. This placental cDNA also codes for a 415-amino-acid Arg-Serpin and publication of the complete sequence will allow its identity to our pcD-1214 clone to be verified.

Several studies (5–7) have identified stimulated monocytes/macrophages as a major source of u-PA. Urokinase is synthesized as a prepropolypeptide (68), but is secreted as a single-chain, zymogenic prourokinase (69). Proteolysis yields a two-chain, active u-PA, the NH2-terminal portion of which binds to specific monocyte-membrane receptors, while the catalytic COOH-terminal domain protrudes from the cell surface to facilitate localized proteolysis (70). The control of tissue proteolysis brought about by monocyte secretion of u-PA appears to be regulated by a corresponding monocyte-derived PAI (PAI-2) that has most recently been characterized as having a pI around 5, and an \( M_r \) on SDS-PAGE of 47,000 (50). Human monocytes/macrophages secrete their specific PAI-2 after stimulation with either LPS (7), PMA (5), or muramyl dipeptide (MDP) (71).

The primary role of PA is to mediate the conversion of the plasma zymogen plasminogen to produce plasmin, an endopeptidase that degrades fibrin (69). Endotoxin-stimulated macrophages are a source of plasmin and have been shown to hydrolyze fibrin (6), probably more effectively by the action of prourokinase rather than mature u-PA (72). However, the tissue-type plasminogen activator (t-PA) and its corresponding fast-acting inhibitor produced predominantly by endothelial cells (PAI-1) have traditionally been considered to be the primary molecules in the homeostatic control of the fibrinolytic system (32, 73). In addition to its potential role in fibrinolysis, u-PA activity has been specifically implicated in the destruction of connective tissue that is a prerequisite to both normal macrophage interstitial migration (74), as well as the analogous process involved in tumor metastasis (13, 14) and stroma production (33).

The assignment of the monocyte Arg-Serpin gene to human chromosome 18 provides a useful marker on a relatively poorly mapped chromosome in the genome and establishes a firm genetic basis for the study of inherited deficiencies in this gene that might be manifested clinically as various fibrinolytic, thrombotic, inflammatory, and even metastatic conditions (75) resulting from unrestricted release of plasmin by PA. Recently the PAI-1 gene was reported to be located on human chromosome 7 (28). The other Serpins mapped to-date include: ATIII to the long arm of chromosome 1 (1q23-q25) (76, 77), API and \( \alpha_1 \)-antichymotrypsin to the long arm of chromosome 14 (14q31-q32) (78, 79), and the recently recognized antiprotease thyroxine-binding globulin, on the long arm of the X-chromosome (80). The u-PA gene has been localized to 10q24-qter (81), whereas the t-PA gene is on chromosome 8p12 (81, 82).

Perhaps the most striking observation from the present study is the demonstration that the monocytic Arg-Serpin gene appears to be very active in endo-
thelial cells after stimulation with LPS (Fig. 2, lanes 7 and 8). This is in contrast to the PAI-1 which has been found to be synthesized constitutively by these cells (26, 29, 83, 84). The possibility that PAI-1 and PAI-2 are both synthesized by endothelial cells may warrant a reassessment of the relative importance of PAI-1 and PAI-2 in endothelial cell control of fibrinolysis and localized vasculitis associated with tumor cell penetration. In some respects PAI-2 could be considered a physiologically more viable candidate for modulation of intravascular PA activity than PAI-1. For example, PAI-1 is secreted by endothelial cells as a latent inhibitor that can only be activated in vitro by treatment with SDS (85) and presumably also requires some cofactor in vivo to achieve full biological activity. The extent to which PAI-2 gene expression is under similar mechanisms of control in both monocytic and endothelial cells is now a major focus of our attention.

Summary

An LPS-stimulated, human monocyte cDNA library was screened for stimulation-specific clones. One clone (pcD-1214) contained a 1.9-kb pair insert that hybridized to a 2,000-nucleotide mRNA expressed by peripheral blood monocytes, the histiocytic lymphoma cell line U937, and umbilical cord endothelial cells. The 415-amino-acid precursor polypeptide predicted from the cDNA (46,596 molecular weight) has a putative 22-residue signal peptide and ~35% homology with members of the serine protease inhibitor (Serpin) superfamily. On the basis of amino acid homology and alignment of COOH-terminal residues within the Serpin-reactive center, the clone pcD-1214 was identified as coding for an Arg-Serpin. Southern blot analysis of human-mouse somatic cell hybrid DNA locates the Arg-Serpin gene on human chromosome 18. A perfect match between amino acid residues 347–376 in this Arg-Serpin and the published sequence of a 30-residue, tryptic peptide from the COOH-terminus of a monocytic plasminogen activator–inhibitor (PAI-2), strongly suggests that the Arg-Serpin encoded by pcD-1214 is PAI-2.

We thank Dr. Eileen Remold-O'Donnell for valuable suggestions and many useful discussions concerning protease inhibitors. The generous gifts of TSST-1-stimulated U937 cells from Dr. Charles Dinarello, and LPS-stimulated THP-1 cells from Dr. Matthew Fenton and Burton Clark are also gratefully acknowledged. The contribution of Dr. William Gilbert in developing the MIT-Whitaker College Computer Facility and constantly updating the array of nucleic acid and protein analysis software is much appreciated. We are also greatly indebted to the members of the Wellesley College advanced Molecular Biology course in 1984 and 1985 for the accumulation and assembly of the DNA sequence. These undergraduates were: Barbara Aguilar, Khandan Baradaran, Lynne Blum, Lilly Chen, Annette Elton, Suzie Fishman, Mary Lee Fleishell, Jennifer Green, Carol Han, Julie Holland, Hilda Hough, Dawn Jones, Katharine Lee, Halina Lusczynski, Annyce Mayer, Nancy Melberg, Elizabeth Mullen, Laurie-Ann Nessralla, Maria Pelidis, Carol Pollison, Helen Roberts, Siri Steinle, Mary Tanner, Diane Taylor, Audrey Un, Dieu-Thu Vo, Martha-Lee Walden, Susan Ward, and Ita Yuen. We are also appreciative of the valuable contributions to this work of Drs. Sheldon Wolff, Alexander Rich, Steven Jobling, and Lee Gehrke.

Received for publication 24 February 1987.
Note added in proof: After the submission of this article for publication, the complete nucleotide sequence of human placental PAI-2 cDNA was reported (86). The near-perfect homology between these two sequences confirms the conclusion that our clone pCD-1214 codes for human PAI-2. Apart from an additional 17 nucleotides in the 5' untranslated region of the monocyte sequence reported here, the two nucleotide sequences differ at only 8 positions out of 1,900. Four of these differences are located within the coding region, although only three result in alterations of the deduced amino acid sequence. These differences are as follows: residue 120, placenta Asp(GAT), monocyte Asn(AAT); residue 393, placenta Pro(CCG), monocyte Pro(CCT); residue 404, placenta Lys(AAG), monocyte Asn(AAC); residue 413, placenta Cys(TGC), monocyte Ser(TCC).

References
1. Werb, Z. 1983. How the macrophage regulates its extracellular environment. Am. J. Anat. 166:237.
2. Takemura, R., and Z. Werb. 1984. Secretory products of macrophages and their physiological functions. Am. J. Physiol. 246:C1.
3. Werb, Z., and S. Gordon. 1975. Elastase secretion by stimulated macrophages: characterization and regulation. J. Exp. Med. 142:361.
4. Unkeless, J. C., S. Gordon, and E. Reich. 1974. Secretion of plasminogen activator by stimulated macrophages. J. Exp. Med. 139:834.
5. Vassalli, J.-D., J.-M. Dayer, A. Wohlwend, and D. Belin. 1984. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J. Exp. Med. 159:1653.
6. Chapman, H. A., Z. Vavrin, and J. B. Hibbs. 1982. Macrophage fibrinolytic activity: identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor. Cell. 28:655.
7. Chapman, H. A., and O. L. Stone. 1985. Characterization of a macrophage-derived plasminogen-activator inhibitor. Similarities with placental urokinase inhibitor. Biochem. J. 230:109.
8. Werb, Z., and S. Gordon. 1975. Secretion of a specific collagenase by stimulated macrophages. J. Exp. Med. 142:346.
9. Mainardi, C. L., J. M. Seyer, and A. H. Kang. 1980. Type-specific collagenolysis: a type V collagen-degrading enzyme from macrophages. Biochem. Biophys. Res. Commun. 97:1108.
10. Osterud, B., U. Lindahl, and R. Seljelid. 1980. Macrophages produce blood coagulation factors. FEBS Lett. 120:41.
11. Bentley, C., B. Zimmer, and U. Hadding. 1981. The macrophage as a source of complement components. Lymphokines. 4:197.
12. Ossowski, L., J. P. Quigley, and E. Reich. 1975. Plasminogen, a necessary factor for cell migration in vitro. In Proteases and Biological Control. E. Reich, D. B. Rifkin, and E. Shaw, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 901–901.
13. Ossowski, L., and E. Reich. 1983. Antibodies to plasminogen activator inhibit tumor metastasis. Cell. 53:611.
14. Mignatti, P., E. Robbins, and D. B. Rifkin. 1986. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell. 47:487.
15. Adams, D. O., K.-J. Kao, R. Farb, and S. V. Pizzo. 1980. Effector mechanisms of cytolytically activated macrophages. II. Secretion of a cytolytic factor by activated macrophages and its relationship to secreted neutral proteases. J. Immunol. 124:293.
16. Vischer, T. L., U. Bretz, and Baggioni, 1976. In vitro stimulation of lymphocytes
by neutral proteinases from human polymorphonuclear leukocyte granules. *J. Exp. Med.* 144:863.

17. Travis, J., and G. S. Salveson. 1983. Human plasma proteinase inhibitors. *Annu. Rev. Biochem.* 52:655.

18. Carrell, R., and J. Travis. 1985. α₁-Antitrypsin and the serpins: variation and countervariation. *Trends Biochem. Sci.* 10:20.

19. Remold-O'Donnell, E. 1985. A fast-acting elastase inhibitor in human monocytes. *J. Exp. Med.* 162:2141.

20. Wiman, B., and D. Collen. 1979. On the mechanism of the reaction between human α₂-antiplasmin and plasmin. *J. Biol. Chem.* 254:9291.

21. Carrell, R. W., and M. C. Owen. 1985. Plakalbumin, α₁-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. *Nature (Lond.)* 317:730.

22. Morse, J. O. 1978. Alpha-1-antitrypsin deficiency. *N. Engl. J. Med.* 290:1099.

23. Hamsten, A., B. Wiman, U. de Faire, and M. Blomback. 1985. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. *N. Engl. J. Med.* 313:1557.

24. Klimetzek, V., and C. Sorg. 1979. The production of fibrinolysis inhibitors as a parameter of the activation state in murine macrophages. *Eur. J. Immunol.* 9:613.

25. Remold-O'Donnell, E., K. Lewandrowski, and C. Vandenbrouke-Grauls. 1982. Two protease inhibitors in peritoneal macrophages. *Fed. Proc.* 41:368.

26. Pannekoek, H., H. Veerman, H. Lambers, P. Diergaard, C. L. Verweij, A.-J. van Zonneveld, and J. A. van Mourik. 1986. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. *EMBO (Eur. Mol. Biol. Organ.) J.* 5:2539.

27. Ny, T., M. Sawdey, D. Lawrence, J. L. Millan, and D. J. Loskutoff. 1986. Cloning and sequence of a cDNA coding for the human β-migrating endothelial-cell-type plasminogen activator inhibitor. *Proc. Natl. Acad. Sci. USA.* 83:6776.

28. Ginsburg, D., R. Zeheb, A. Y. Yang, U. M. Rafferty, P. A. Andreasen, L. Nielsen, K. Dano, R. V. Lebo, and T. D. Gelehrter. 1986. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. *J. Clin. Invest.* 78:1675.

29. Erickson, L. A., C. M. Hekman, and D. J. Loskutoff. 1985. The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. *Proc. Natl. Acad. Sci. USA.* 82:8710.

30. Kruithof, E. K. O., J.-D. Vassalli, W.-D. Schleuning, R. J. Mattaliano, and F. Bachmann. 1986. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U937. *J. Biol. Chem.* 261:11207.

31. Jaffe, E. A. 1983. Vascular function in hemostasis. In *Hematology.* 3rd ed. W. J. Williams, E. Beutler, A. J. Ersliev, and M. A. Lichtman, editors. McGraw-Hill Book Co., New York. 1277–1287.

32. Marder, V. J., and C. W. Francis. 1983. Clinical aspects of fibrinolysis. In *Hematology.* 3rd ed. W. J. Williams, E. Beutler, A. J. Ersliev, and M. A. Lichtman, editors. McGraw-Hill Book Co., New York. 1462–1473.

33. Dvorak, H. F. 1986. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. *N. Eng. J. Med.* 315:1650.

34. Auron, P. E., A. C. Webb, L. J. Rosenwasser, S. F. Mucci, A. Rich, S. M. Wolff, and C. A. Dinarello. 1984. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. *Proc. Natl. Acad. Sci. USA.* 81:7907.

35. Webb, A. C., P. E. Auron, A. Rich, L. J. Rosenwasser, S. M. Wolff, and C. A. Dinarello. 1985. Molecular cloning of human interleukin-1 precursor cDNA and its expression in monkey cells. In *Cellular and Molecular Biology of Lymphokines.* C. Sorg and A. Schimpl, editors. Academic Press, New York. 685–695.
36. Okayama, H., and P. Berg. 1983. A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells. Mol. Cell. Biol. 3:280.
37. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA. 74:5463.
38. Messing, J. 1983. New M13 vectors for cloning. Methods Enzymol. 101:20.
39. Dale, R. M. K., B. A. McClure, and J. P. Houckins. 1985. A rapid single-stranded cloning strategy for producing a sequential series of overlapping clones for use in DNA sequencing: Application to sequencing the corn mitochondrial 18S rDNA. Plasmid. 13:31.
40. Staden, R. 1984. A computer program to enter DNA gel reading data into a computer. Nucleic Acids Res. 12:499.
41. Devereux, J., P. Haebeli, and O. Smithies. 1984. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res. 12:387.
42. Dayhoff, M. O. 1979. Atlas of Protein Sequence and Structure. Vol. 5. Suppl. 3. National Biomedical Research Foundation, Washington, DC. 375 pp.
43. Dayhoff, M. O., W. C. Barker, and L. T. Hunt. 1983. Establishing homologies in protein sequences. Methods Enzymol. 91:524.
44. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 545 pp.
45. Saman, E. 1986. A simple and sensitive method for detection of nucleic acids fixed on nylon-based filters. Gene Anal. Tech. 3:1.
46. Webb, A. C., K. L. Collins, P. E. Aaron, R. L. Eddy, H. Nakai, M. G. Byers, L. L. Haley, W. M. Henry, and T. B. Shows. 1986. Interleukin-1 gene (IL1) assigned to long arm of human chromosome 2. Lymphokine Res. 5:77.
47. Shows, T. B., A. Y. Sakaguchi, and S. L. Naylor. 1982. Mapping the human genome, cloned genes, DNA polymorphisms and inherited disease. Adv. Human Genet. 12:341.
48. Shows, T. B., R. Eddy, L. Haley, M. Byers, M. Henry, T. Fujita, H. Matsui, and T. Taniguchi. 1984. Interleukin 2 (IL2) is assigned to human chromosome 4. Somatic Cell Mol. Genet. 10:315.
49. Sakaguchi, A. Y., and T. B. Shows. 1982. Coronaviruse 229E susceptibility in mammalian hybrids is located on human chromosome 15. Somatic Cell Genet. 8:83.
50. Blomster-Hautamaa, D. A., B. N. Kreiswirth, J. S. Kornblum, R. P. Novick, and P. M. Schlievert. 1986. The nucleotide and partial amino acid sequence of toxic shock syndrome toxin-1. J. Biol. Chem. 261:15783.
51. Sauder, D. N. 1985. Epidermal cell-derived thymocyte activating factor (ETAF): A mediator of inflammatory and immune reactions. In The Physiologic, Metabolic, and Immunologic Actions of Interleukin-1. M. J. Kluger, J. J. Oppenheim, and M. C. Powanda, editors. Alan R. Liss, Inc., New York. 365–373.
52. Mitchell, R. L., L. Zokas, R. D. Schreiber, and I. M. Verma. 1985. Rapid induction of the expression of proto-oncogene fos during human monocytic differentiation. Cell. 40:209.
53. Staden, R. 1984. Graphic methods to determine the function of nucleic acid sequences. Nucleic Acids Res. 12:521.
54. Staden, R. 1984. Measurements of the effects that coding for a protein has on a DNA sequence and their use for finding genes. Nucleic Acids Res. 12:551.
55. Kozak, M. 1984. Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res. 12:857.
56. Proudfoot, N. J., and G. G. Brownlee. 1976. 3' non-coding region sequences in eucaryotic messenger RNA. Nature (Lond.). 263:211.
57. Caput, D., B. Buteler, K. Hartog, R. Thayer, S. Brown-Shimer, and A. Cerami. 1986. Identification of a common nucleotide sequence in the 3'-untranslated region of
mRNA molecules specifying inflammatory mediators. Proc. Natl. Acad. Sci. USA. 83:1670.

58. Shaw, G., and R. Kamen. 1986. A conserved AU sequence from the 3’ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell. 46:659.

59. Von Heijne, G. 1983. Patterns of amino acids near signal-sequence cleavage sites. Eur. J. Biochem. 133:17.

60. Perlman, D., and H. O. Halvorson. 1983. A putative signal peptidase recognition site and sequence in eukaryotic and prokaryotic signal peptides. J. Mol. Biol. 167:391.

61. Bause, E. 1983. Structural requirements of N-glycosylation of proteins. Studies with proline peptides as conformational probes. Biochem. J. 209:331.

62. Lipman, D. J., and W. R. Pearson. 1985. Rapid and sensitive protein similarity searches. Science (Wash. DC). 227:1435.

63. Hunt, L. T., and M. O. Dayhoff. 1980. A surprising new protein superfamily containing ovalbumin, antithrombin III, and alpha,-proteinase inhibitor. Biochem. Biophys. Res. Commun. 95:864.

64. Toh, H., H. Hayashida, and T. Miyata. 1983. Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature (Lond.). 305:827.

65. Liu, D., C. C. Simonsen, and A. D. Levinson. 1984. Initiation of translation at internal AUG codons in mammalian cells. Nature (Lond.). 309:82.

66. Peabody, D. S., and P. Berg. 1986. Termination-reinitiation occurs in the translation of mammalian cell mRNAs. Mol. Cell. Biol. 6:2695.

67. Ye, R. D., J. W. Tze-Chein, and J. E. Sadler. 1986. Characterization of cDNA for a plasminogen activator inhibitor from human placenta. Circulation. 74:247.

68. Salerno, G., P. Verde, M. L. Nolli, A. Corti, H. Szots, T. Meo, J. Johnson, S. Bullock, G. Cassani, and F. Blasi. 1984. Monoclonal antibodies to human urokinase identify the single-chain pro-urokinase precursor. Proc. Natl. Acad. Sci. USA. 81:110.

69. Wu, T.-C., W.-D. Schleuning, and E. Reich. 1982. Isolation and characterization of urokinase from human plasma. J. Biol. Chem. 257:3276.

70. Stoppelli, M. P., M. Corti, A. Soffientini, G. Cassani, F. Blasi, and R. K. Assoian. 1985. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. USA. 82:4929.

71. Golder, J. P., and R. W. Stephens. 1983. Minactivin: a human monocyte product which specifically inactivates urokinase-type plasminogen activators. Eur. J. Biochem. 136:517.

72. Gurewich, V., R. Pannell, S. Louie, P. Kelley, R. L. Suddith, and R. Greenlee. 1984. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J. Clin. Invest. 73:1731.

73. Colleen, D. 1980. On the regulation and control of fibrinolysis. Thromb. Haemostasis. 43:77.

74. Dano, K., P. A. Andreasen, J. Grondaal-Hansen, B. Kristensen, L. S. Nielsen, and L. Skriver. 1985. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res. 44:146.

75. Kruithof, E. K. O., A. Gudinchet, C. Tran-Thang, A. Ransijn, and F. Bachmann. 1985. Antiactivator levels in various disease states. In Progress in Fibrinolysis. Vol. 7. Academic Press, New York. 130–132.

76. Kao, F. T., H. G. Morse, M. L. Law, A. Lidsky, T. Chandra, and S. L. C. Woo. 1984. Genetic mapping of the structural gene for antithrombin III to human chromosome 1. Hum. Genet. 67:34.
77. Bock, S. C., J. F. Harris, I. Balazs, and J. M. Trent. 1985. Assignment of the human antithrombin III structural gene to chromosome 1q23-25. Cytogenet. Cell Genet. 39:67.
78. Darlington, G. J., K. H. Astrin, S. P. Muirhead, R. J. Desnick, and M. Smith. 1982. Assignment of human alpha-1-antitrypsin to chromosome 14 by somatic cell hybrid analysis. Proc. Natl. Acad. Sci. USA. 79:870.
79. Rabin, M., M. Watson, W. R. Breg, V. Kidd, S. L. C. Woo, and F. H. Ruddle. 1985. Human alpha-1-antichymotrypsin (AACT) and alpha-1-antitrypsin (PI) genes map to the same region on chromosome 14. Int. Workshop Human Gene Mapping Cytogenet. Cell Genet., 8th, Helsinki. 40:728.
80. Flink, I. L., T. J. Bailey, T. A. Gustafson, B. E. Markham, and E. Morkin. 1986. Complete amino acid sequence of human thyroxine-binding globulin deduced from cloned DNA: Close homology to the serine antiproteases. Proc. Natl. Acad. Sci. USA. 83:7708.
81. Rajput, B., F. F. Degen, E. Reich, R. L. Eddy, and T. B. Shows. 1985. Mapping of tissue plasminogen activator (PLAT) to chromosome 8 and urokinase (PLAU) to chromosome 10 in humans. Int. Workshop Human Gene Mapping Cytogenet. Cell Genet., 8th, Helsinki. 40:728.
82. Yang-Feng, T. L., G. Opdenakker, G. Volckaert, and U. Francke. 1985. Mapping of the human tissue-type plasminogen activator (PLAT) gene to chromosome 8 (8p12-q11.2). Int. Workshop Human Gene Mapping Cytogenet. Cell Genet., 8th, Helsinki. 40:784.
83. Loskutoff, D. J., J. A. van Mourik, L. A. Erickson, and D. Lawrence. 1983. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc. Natl. Acad. Sci. USA. 80:2956.
84. van Mourik, J. A., D. A. Lawrence, and D. J. Loskutoff. 1984. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J. Biol. Chem. 259:14914.
85. Hekman, C. M., and D. J. Loskutoff. 1985. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J. Biol. Chem. 260:11581.
86. Ye, R. D., T-C. Wun, and J. E. Sadler. 1987. cDNA cloning and expression in Escherichia coli of a plasminogen activator inhibitor from human placenta. J. Biol. Chem. 262:3718.